Department of Physical Therapy Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-city, Japan.
Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Immunol Med. 2022 Sep;45(3):168-174. doi: 10.1080/25785826.2022.2046307. Epub 2022 Apr 2.
Remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE), a rheumatic disease affecting the elderly, responds well to corticosteroids; however, our RS3PE patients' corticosteroid therapy is longer than expected. Elderly-onset rheumatoid arthritis (EORA) patients are reported to be at a significantly increased risk for steroid-related side effects including cardiovascular diseases (CVDs). To clarify the complications during a 1-year follow-up in corticosteroid-treated RS3PE patients compared to EORA patients. We retrospectively analyzed the records of 47 RS3PE patients (28 men, 19 women, age 78.4 ± 7.5 years) and 46 EORA patients (10 men, 36 women; 77.0 ± 6.8 yrs) to compare the complications over a 1-year follow-up. The RS3PE and EORA groups' average initial PSL doses were 16.5 ± 7.2 mg/day and 7.3 ± 4.6 mg/day, respectively. During the 1-year follow-up after treatment, there was no significant increase in CVDs in both groups. However, infections occurred in nine RS3PE patients, which is a significantly higher incidence compared to the EORA patients with infections ( = 3). The initial PSL dose was the independent variable associated with the incidence of infection. Infections were significantly increased during elderly RS3PE patients' steroid therapy. The initial corticosteroid dose was an infection-risk factor.Key messagesInfections are increased during steroid therapy in elderly patients with RS3PE syndrome.The initial dose of corticosteroids was one of the risk factors for infections.
缓解性血清阴性对称性滑膜炎伴凹陷性水肿综合征(RS3PE)是一种影响老年人的风湿性疾病,对皮质类固醇反应良好;然而,我们的 RS3PE 患者的皮质类固醇治疗时间比预期的要长。据报道,老年发病的类风湿关节炎(EORA)患者发生与类固醇相关的副作用(包括心血管疾病(CVDs))的风险显著增加。为了明确与皮质类固醇治疗的 RS3PE 患者相比 EORA 患者在 1 年随访期间的并发症。我们回顾性分析了 47 例 RS3PE 患者(28 名男性,19 名女性,年龄 78.4±7.5 岁)和 46 例 EORA 患者(10 名男性,36 名女性;77.0±6.8 岁)的记录,以比较 1 年随访期间的并发症。RS3PE 和 EORA 组的平均初始 PSL 剂量分别为 16.5±7.2mg/天和 7.3±4.6mg/天。在治疗后 1 年的随访期间,两组均未出现 CVD 显著增加。然而,有 9 例 RS3PE 患者发生感染,与 EORA 患者感染( = 3)相比发生率显著更高。初始 PSL 剂量是与感染发生率相关的独立变量。在老年 RS3PE 患者的类固醇治疗期间,感染显著增加。初始皮质类固醇剂量是感染的危险因素。
RS3PE 综合征老年患者在类固醇治疗期间感染增加。
皮质类固醇的初始剂量是感染的危险因素之一。